CAR-T for R/R B-NHL

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05420493` - Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma	Phase 1
Completed	`NCT00005803` - Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03233204` - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Phase 2
Recruiting	`NCT04545762` - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1
Active, not recruiting	`NCT03583424` - Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04923789` - A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
Active, not recruiting	`NCT04150913` - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity	Phase 2
Active, not recruiting	`NCT03213691` - Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Recruiting	`NCT06026319` - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT06119685` - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers	Phase 1/Phase 2
Recruiting	`NCT05892718` - A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors	Phase 1
Active, not recruiting	`NCT04284774` - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03220035` - Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Terminated	`NCT02420795` - Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT03778619` - MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin	Phase 1/Phase 2
Active, not recruiting	`NCT03213678` - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Active, not recruiting	`NCT02568553` - Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Phase 1
Active, not recruiting	`NCT03698994` - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Active, not recruiting	`NCT03213665` - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2

NCT number	NCT03196830
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact	Cai-Xia Li
Phone	86 512 67781856
Email	licaixia@suda.edu.cn
Status	Recruiting
Phase	Phase 2
Start date	June 1, 2017
Completion date	May 31, 2021

CAR-T for R/R B-NHL

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms